Dahhan v. OvaScience, Inc., et al.

"Among other things, the Complaint alleges that, during the Class Period, the OvaScience Defendants knowingly or recklessly misrepresented and concealed material facts regarding the efficacy and commercial viability of AUGMENT. More specifically, the Complaint alleges that throughout the Class Period, the OvaScience Defendants made numerous public statements that led investors to believe that AUGMENT worked, and that there was significant demand from patients, which caused OvaScience’s common stock to allegedly trade at artificially inflated prices during the Class Period. The Complaint further alleges that the price of OvaScience stock declined when the true facts concerning the OvaScience Defendants’ alleged misrepresentations and omissions were revealed, resulting in financial losses to those who purchased or acquired OvaScience common stock during the Class Period at the inflated prices."